Investment Thesis
Abbott demonstrates solid fundamental health with strong profitability metrics, robust cash generation, and excellent financial leverage. Revenue growth of 5.7% combined with consistent net margins of 14.7% and FCF margin of 16.7% indicates a mature, cash-generative business with effective operational execution.
ABT Strengths
- Exceptional liquidity with current ratio of 1.58x and quick ratio of 1.18x, well-positioned to meet obligations
- Outstanding interest coverage of 57.1x and conservative debt/equity of 0.25x demonstrate fortress balance sheet with minimal financial distress risk
- Strong free cash flow generation of $7.4B with 16.7% FCF margin, enabling capital allocation flexibility and shareholder returns
- High operating efficiency with 18.2% operating margin and 14.7% net margin, indicating competitive moat and pricing power
- Significant insider activity with 26 Form 4 filings suggesting management confidence
ABT Risks
- Modest revenue growth of 5.7% YoY signals mature market conditions and limited organic expansion opportunities in core pharma
- Concerning 51.3% YoY decline in diluted EPS despite flat net income growth suggests increased share dilution or non-recurring charges requiring investigation
- Gross margin of only 9.9% is exceptionally low for pharmaceutical sector, indicating either unfavorable product mix, pricing pressure, or data quality issues that need clarification
- Limited visibility into balance sheet composition with total liabilities not disclosed, hampering complete leverage and solvency assessment
Key Metrics to Watch
- Revenue growth trajectory and organic vs. inorganic breakdown to assess sustainability
- Gross margin expansion/compression and product mix evolution in subsequent quarters
- Free cash flow consistency and capital allocation priorities (dividends, buybacks, debt reduction, acquisitions)
- EPS driver analysis to understand dilution source and manage shareholder value expectations
- Debt levels and refinancing activities given current interest rate environment
ABT Financial Metrics
Revenue
$44.3B
Net Income
$6.5B
EPS (Diluted)
$3.72
Free Cash Flow
$7.4B
Total Assets
$86.7B
Cash Position
$8.5B
ABT Profitability Ratios
Gross Margin
9.9%
Operating Margin
18.2%
Net Margin
14.7%
ROE
12.5%
ROA
7.5%
FCF Margin
16.7%
ABT Balance Sheet & Liquidity
Current Ratio
1.58x
Quick Ratio
1.18x
Debt/Equity
0.25x
Debt/Assets
0.0%
Interest Coverage
57.11x
Long-term Debt
$12.9B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 17, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI